American developer of oral drug sustained-release technology: Lyndra Therapeutics, Inc

Lyndra Therapeutics, Inc., founded in 2015, is headquartered in Watertown, Massachusetts, USA, Lyndra Therapeutics is developing oral ultra long effect and sustained release (sustained release) therapy for the treatment of central nervous system (CNS) diseases, which is applicable to multiple treatment fields, including approved drugs, which helps the medical community to ensure that patients better comply with drug treatment and improve health outcomes, and also helps to reduce medical costs.

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Lyndra Therapeutics, Inc

Lyndra Therapeutics is a pioneer of long-term oral therapy, which is a potential major progress in the field of oral drug delivery. Lyndra's proprietary LYNX ™ The drug delivery platform is designed to deliver drugs (sustained-release) in oral form for a week or more. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Lyndra seeks to make significant progress in oral drug delivery, and the Lyndra team is working together through LYNX ™ The drug delivery platform provides a variety of treatment methods that change the rules of the game to meet the needs of patients and nursing staff. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Lynx proprietary to Lyndra ™ Drug delivery platform (Lynx ™ Drug Delivery Platform） The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

LYNX of Lyndra Therapeutics ™ Drug delivery platform is an innovation of medicine. It is designed to provide long-term treatment in oral form through standard size capsules. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Working principle of LYNX ™: The capsule contains the pharmaceutical elements of the dosage form, which is composed of arms connected to the flexible core, and is designed to make the dosage form reach and maintain the desired shape in the stomach, so as to prevent it from passing through the pylorus (the opening between the stomach and the small intestine). The connector connecting the dosage form arm and the core is designed to soften and decompose at the completion of the dose cycle. These components are then designed to safely exit the body through the pylorus. For patients and nursing staff, this innovative solution means that drugs may have a longer duration and better effect in pharmacokinetics than current immediate release or delayed release oral preparations. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Lyndra's revolutionary LYNX ™ Drug delivery platforms are more than just extended release. LYNX ™ drug delivery platform adopts a novel long-term oral dosage form method, aiming to achieve stable and consistent drug release throughout the 7-day dose cycle, which may reduce the peak and trough of daily dose. Phase II data of oral risperidone (LYN-005) per week showed that LYN-005 rapidly reached the treatment level in patients, provided continuous risperidone drug level, repeated the weekly dose interval and reduced peak drug exposure compared with daily risperidone. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Lyndra Oral Drug Delivery Pipeline The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Lyndra's LYNX ™ Drug delivery platforms have the potential to be widely used in many therapeutic areas - including approved drugs and currently under development drugs. The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

The article originates from the home of American stocks | encyclopedia of American stocks | account opening and investment of American and Hong Kong stocks- https://www.mg21.com/lyndra.html

Lyndra Therapeutics, Inc. Historical Encyclopedia

Lyndra Therapeutics began in 2015, and originated from a revolutionary technology of the Langer Lab at MIT. Robert Langer (Sc.D.), Giovanni Traverso (M.D., Ph.D.), Andrew Bellinger (M.D., Ph.D.) and Amy Schulman (J.D.) co founded this company, aiming to develop, expand and eventually commercialize this company, which will eventually become LYNX ™ Technology of drug delivery platform. Since its establishment, Lyndra has made rapid progress, developed 19 therapies in the laboratory, promoted four therapeutic products to the clinical stage, and verified the feasibility of its platform through a variety of APIs.

• In 2015, Lyndra Therapeutics was founded by Robert Langer, Doctor of Science, Giovanni Traverso, Doctor of Medicine and Doctor of Philosophy, Andrew Bellinger, Doctor of Medicine and Doctor of Philosophy, and Amy Schulman, Doctor of Law.
• In 2016, Lyndra started the preclinical trial of LYNX drug delivery platform with the help of US $300000 from the National Institutes of Health (NIH). The data proves that the platform is effective.
• In 2017, LYNX drug delivery platform was validated in human subjects. Lyndra completed round A financing of 23 million dollars, and abbvie (AbbVie) has established a partnership of US $105 million and received a grant of US $10 million (from Bill&Melinda Gates Foundation And the National Institutes of Health).
• In 2018, the safety and predictable pharmacokinetics of LYNX drug delivery platform have been proved in Phase 1 clinical trial. Lyndra received additional grants (donations) from NIH ($18 million) and the Bill and Melinda Gates Foundation ($13 million).
• In 2019, the subsequent Phase I study showed that a LYNX capsule contained two combination products with different APIs, indicating that the two active ingredients had the same pharmacokinetics at the target level, were insensitive to food effects, and provided further evidence for the safety of the LYNX oral drug delivery platform. Lyndra completed round B financing of 60 million dollars, and Gilead Established a partnership of $122 million, and obtained NIH ($19 million) and the United States national defense Additional allocations (contributions) from the Ministry ($3 million).
• In 2020, Lyndra continued to develop and launched the first phase 2 study (weekly oral risperidone (LYN-005) IND submission and phase 1 and phase 2 clinical trials) using the LYNX drug delivery platform. Lyndra opened a state-of-the-art GMP manufacturing facility in Lexington, Massachusetts. Lyndra also received additional funding from the Bill and Melinda Gates Foundation ($2 million) and NIH ($1 million).
• In 2021, weekly oral risperidone (LYN-005) for the treatment of schizophrenia has reached its phase II end point, and food The phase II closing meeting held by the Drug Administration (FDA) achieved positive results and established the way for approval. Weekly oral L-methadone (LYN-014) has submitted an IND application for maintenance treatment of opiate use disorders, and the project has been designated by FDA as a fast track. Lyndra completed round C financing of $60.5 million and increased its number of employees to more than 100.
• In 2022, weekly oral risperidone (LYN-005) is planned to start key trials, and Lyndra will promote several new assets to the clinic. Start the preclinical study of aripiprazole (LYN-006) once a week for the second CNS asset.

Lyndra Therapeutics, Inc. Financing Encyclopedia

In April 2017, Lyndra Therapeutics, Inc. completed a round A financing of $23 million led by Polaris Partners, followed by Yonghua Capital, GF Securities, Quark Venture, Mass General Brigham, etc.

In February 2019, Lyndra Therapeutics, Inc. completed a round B financing of US $60.9 million, Polaris Partners、Yonghua Capital、 Invus 、 Gilead Sciences、Bill & Melinda Gates Foundation And so on.

In June 2021, Lyndra Therapeutics, Inc. completed the US $60.5 million round C financing led by AIG Investments, Polaris Partners Invus , Gilead Sciences, THE CATALYTIC IMPACT FOUNDATION (CIF), Quark Venture, etc.

In June 2023, Lyndra will complete round D financing of USD 20.3 million and Sarissa Capital Management will invest exclusively.

In December 2023, Lyndra Therapeutics, Inc. completed the US $101 million E-round financing led by Sarissa Capital Management, and Polaris Partners and Sun Pharmaceutical Industries co invested.

Lyndra Therapeutics, Inc. US equity investment

Unlisted company ， Company official website , waiting for Lyndra Therapeutics, Inc IPO Listing.